38% Silver Diamine Fluoride
(25% Silver, 5% Fluoride, 8% Ammonia)
Silver Diamine fluoride is an odourless liquid that:
- Outperforms other anti-cavity treatments in killing decay-causing bacteria
- Quick application (less than 5 minutes)
- User-friendly, no need for:
- Air or water
Silver Diamine Fluoride halts the progress of an existing cavity.
It’s great for children 3 years or older who have difficulty sitting through a filling appointment. It will delay the progression of a cavity until the child is older and is able to sit through a regular appointment, reducing the probability the child will require IV sedation (general anaesthesia) for treatment.
Silver Diamine Fluoride is also great for adults with medical issues that prevent them from getting a more permanent treatment such as a filling.
The process of applying Silver Diamine Fluoride is as very straightforward:
- The surface of the affected tooth is dried and isolated with cotton rolls
- Silver Diamine Fluoride is applied to the affected area and allowed to soak for 60 seconds
- If no varnish is applied, the surface is allowed to dry completely
The process is repeated in 1-3 week(s), and then reapplied at intervals of 6 months to 1 year.
The decayed areas of teeth treated with Silver Diamine Fluoride may become stained. Staining is actually the indicator of antimicrobial effectiveness. Silver Diamine Fluoride will not stain sound or healthy enamel or dentin.
In 2016, Silver Diamine Fluoride, marketed under the brand Advantage Arrest, was granted the first ever FDA breakthrough therapy designation for an oral care product for its ability to stop tooth decay. This designation represents the FDA’s effort to address an unmet, serious, life-threatening medical need where there is no available therapy and to expedite the review of such products. The designation was granted based on the FDA review of 10 worldwide randomized clinical trials evaluating silver diamine fluoride for cavities in children aged 3-9 or adults aged 60-89. Collectively these trials involved 1,500 subjects who were monitored for 1-3 years.